Heat Biologics Inc., a clinical-stage biopharmaceutical company focused on developing therapies to modulate the immune system, has appointed Paul Tebbey, Ph.D. as senior vice president of Product Development and Portfolio Strategy.
 
Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer.
 
Tebbey’s research, development and commercial launch experiences include novel monoclonal antibodies (STELARA first-in-IL-12/23 class, REMICADE & HUMIRA anti-TNF mAbs), complex vaccines (PREVNAR novel conjugated vaccine, influenza and respiratory syncytial virus), biosimilars as well as targeted oncolytic small molecules (VENCLEXTA). Tebbey received a Ph.D. in Microbiology and Immunology from East Carolina University School of Medicine where his research focused on T lymphocyte cell signaling, immunosuppression and transformation and completed his postdoctoral studies at Vanderbilt University focusing on the regulation of gene expression. Tebbey’s publications include over 40 peer-reviewed articles that span immunology, immune-mediated and infectious diseases, clinical trial design as well as pharmaceutical strategy planning and brand success.
 
Jeff Wolf, chief executive officer of Heat, commented, “Paul’s background and proven track record will help advance our current and planned clinical programs, as well as our extensive ongoing R&D and emerging biosecurity initiatives.”
 
Tebbey said, “I am excited to join Heat Biologics at this exciting time. Heat has developed a robust clinical platform spanning both oncology and infectious diseases. On the R&D front, I look forward to helping advance numerous, value-driving clinical programs as well as Skunkworx, which is utilizing integrated computational and bioinformatic analysis with the goal of accelerating the speed and reducing the costs associated with drug development.”